AbCellera Biologics Inc.
ABCLNASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $3.61B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $2.75$15.02
- Volume (live)
- -
- Avg. volume (3M)
- 5.07M
AbCellera Biologics (ABCL) Stock Price & Financial Analysis
AbCellera Biologics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $11.08 - $11.89 |
|---|---|
| 52-Week High | $15.02 |
| 52-Week Low | $2.75 |
| Open | $11.45 |
| Volume (last close) | 3.02M |
| Average Volume (3M) | 5.07M |
| Revenue (TTM) | 66.17M |
|---|---|
| Net Income (TTM) | -164.66M |
| Free Cash Flow (TTM) | -119.67M |
| EPS (TTM) | −$0.55 |
| Profit Margin | -248.83% |
| Operating Margin | -330.31% |
| Return on Equity (ROE) | -18.38% |
| Debt to Equity | 0.15 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 3.61B |
|---|---|
| Shares Outstanding | 305.56M |
| Price to Sales (P/S) | 54.58 |
| Price to Book (P/B) | 4.03 |
| EV/EBITDA | -19.99 |
| 50-Day MA | $12.07 |
|---|---|
| 200-Day MA | $6.52 |
| 1-Year Change | +99.12% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
AbCellera Biologics at a Glance
As of the Oct 23, 2026 close, AbCellera Biologics (ABCL) has a market capitalization of $3.61B. The stock trades at 54.6× sales. Over the trailing twelve months it lost $164.66M on revenue of $66.17M and burned $119.67M of free cash flow. Revenue grew 101.3% year over year.
As of its latest reported balance sheet, it holds $120.06M in cash and securities against $135.62M of debt, a net debt position of $15.55M.
AbCellera Biologics does not currently pay a dividend.
The share price is up 99.1% over the past year. At $11.82 (the Oct 23, 2026 close) it sits within its 52-week range of $2.75 to $15.02, above its 200-day moving average of $6.52.
Based on 11 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $16.78, 42.0% above the Oct 23, 2026 close.
Frequently Asked Questions About AbCellera Biologics
What is the current stock price for ABCL?
As of the Oct 23, 2026 close, ABCL stock trades at $11.82. The 52-week range is $2.75–$15.02, with a day range of $11.08–$11.89.
What is the P/E ratio for ABCL?
The P/E ratio (Price-to-Earnings) for ABCL is shown in the Key Statistics section. This valuation metric helps compare AbCellera Biologics Inc. to industry peers.
Does ABCL pay dividends?
AbCellera Biologics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for ABCL?
Based on ratings from 11 professional analysts over the last 90 days, the consensus for ABCL is Buy. The average 12-month price target is $16.78, a 42.0% upside from the Oct 23, 2026 close of $11.82.
What is the market cap of ABCL?
As of the Oct 23, 2026 close, AbCellera Biologics's market capitalization is $3.61B, classifying it as a mid-cap company. AbCellera Biologics operates in the Healthcare sector within the Biotechnology industry.